Sanofi releases AVAXIM Junior in the UK
Therapy provides immunisation against infection caused by hepatitis A in children aged 12 months to 15 years
Read More
Tag: avaxim
- RougeTx launches with $58 million series A financing for HHT therapy
- Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease
- Bespak and SNBL agree global access deal for FDA‑approved nasal device
- NEMLUVIO data show sustained three‑year responses in atopic dermatitis
- SMC accepts AQUIPTA for eligible migraine patients in Scotland
